Cresco Labs (CRLBF) Capital Leases (2023 - 2026)

Cresco Labs' (CRLBF) quarterly Capital Leases came in at $17.6 million in Q1 2026, down 3.91% on a QoQ basis from $18.3 million in Q4 2025.

Cresco Labs (CRLBF) Capital Leases (2023 - 2026) Analysis & Trends

Cresco Labs (CRLBF) has 3 years of Capital Leases data on file, last reported at $17.6 million in Q1 2026.

Quarterly Capital Leases changed N/A year-over-year to $17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.6 million (changed N/A YoY) and the FY2025 annual result came in at $18.3 million, changed N/A from the prior year.
Capital Leases retreated to $17.6 million in Q1 2026, from $18.3 million in the prior quarter.
In the past five years, Capital Leases ranged from a high of $22.4 million in Q4 2023 to a low of $17.6 million in Q1 2026.
A 3-year average of $19.4 million and a median of $18.3 million in 2025 frame the typical range for Capital Leases.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-
10	Cresco Labs	295.09 Mn	230.98 Mn	86.95 Mn

Download Data